<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79917">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065011</url>
  </required_header>
  <id_info>
    <org_study_id>LTS13619</org_study_id>
    <secondary_id>US1/002/13</secondary_id>
    <nct_id>NCT02065011</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B</brief_title>
  <official_title>An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the long-term safety and tolerability of UshStat® in patients with Usher
      syndrome type 1B

      Secondary Objective:

      To assess long-term safety and biological activity of UshStat®
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2034</completion_date>
  <primary_completion_date type="Anticipated">April 2034</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events.</measure>
    <time_frame>During the first 5 years of follow up, every six months, then on an annual basis for a subsequent 10 years</time_frame>
    <description>The number and percentage of patients with treatment emergent adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ocular safety assessments</measure>
    <time_frame>During the first 5 years of follow up, every six months, then on an annual basis for a subsequent 10 years</time_frame>
    <description>Best Corrected Visual Acuity (BCVA), Slit-lamp, Funduscopy, Intraocular Pressure, Lab parameters, concomitant meds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay in retinal degeneration</measure>
    <time_frame>During the first 5 years of follow up, every six months, then on an annual basis for a subsequent 10 years</time_frame>
    <description>Measured as change from baseline in function relative to untreated contralateral eye on: BCVA, kinetic, static perimetry, microperimetry, autofluorescence, ERG, OCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Usher Syndrome</condition>
  <arm_group>
    <arm_group_label>Long-term follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Long-term follow up of patients who received UshStat in a previous study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UshStat</intervention_name>
    <description>Long-term follow up of patients who received UshStat in a previous study</description>
    <arm_group_label>Long-term follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide signed and dated written informed consent (and if appropriate assent) and any
             locally required authorization eg, Health Insurance Portability and Accountability
             Act (HIPAA).

          -  Must have been enrolled in Protocol TDU13600

          -  Must have received a subretinal injection of UshStat®

        Exclusion Criteria:

          -  Did not receive UshStat® as part of the TDU13600 protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Weleber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Casey Eye Institute, Portland Oregon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Usher Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
